Final results of a placebo controlled, Phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS).

被引：0
|
作者：
Fox, E. [1 ,2 ]
Lovett-Racke, A. [3 ]
Gormley, M. [3 ]
Liu, Y. [3 ]
Wray, S. [4 ]
Shubin, R. [5 ]
Petracca, M. [6 ]
Inglese, M. [6 ]
Power, S. [7 ]
Bosco, J. [7 ]
Mok, K. [7 ]
Weiss, M. [7 ]
Eubanks, J. [7 ]
机构：
[1] Cent Texas Neurol Consultants, Round Rock, TX USA
[2] Univ Texas Austin, Dell Med Sch, Austin, TX 78712 USA
[3] Ohio State Univ, Dept Microbial Infect & Immun, Columbus, OH 43210 USA
[4] Hope Neurol, Knoxville, TN USA
[5] SC3 Res Grp, Arcadia, CA USA
[6] Mt Sinai, Neurol, New York, NY USA
[7] TG Therapeut, New York, NY USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
229
引用
收藏
页码：87 / 87
页数：1
相关论文
共 50 条
  • [31] A phase I dose-escalation trial of ublituximab (TG-1101), a novel anti-CD20 monoclonal antibody (mAb), for rituximab relapsed/refractory B-cell lymphoma patients
    Deng, Changchun
    Amengual, Jennifer Effie
    Schreeder, Marshall T.
    Clark-Garvey, Sean
    Patterson, Molly
    Miskin, Hari
    Sportelli, Peter
    O'Connor, Owen A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [32] Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
    Salles, Gilles
    Morschhauser, Franck
    Lamy, Thierry
    Milpied, Noel
    Thieblemont, Catherine
    Tilly, Herve
    Bieska, Gabi
    Asikanius, Elina
    Carlile, David
    Birkett, Joe
    Pisa, Pavel
    Cartron, Guillaume
    BLOOD, 2012, 119 (22) : 5126 - 5132
  • [33] Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study
    Agius, Mark A.
    Klodowska-Duda, Gabriela
    Maciejowski, Maciej
    Potemkowski, Andrzej
    Li, Jing
    Patra, Kaushik
    Wesley, Jacob
    Madani, Soraya
    Barron, Gerard
    Katz, Eliezer
    Flor, Armando
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (02) : 235 - 245
  • [34] Zuberitamab, an innovative anti-CD20 monoclonal antibody, for patients with primary immune thrombocytopenia in China: a randomized, double-blind, placebo-controlled, phase 2 study
    Xu, Min
    Shu, Jinhui
    Qian, Shenxian
    Guo, Jingming
    Gong, Yuping
    Huang, Ruibin
    Wang, Shuye
    Zhou, Zeping
    Yuan, Guolin
    Huang, Meijuan
    Lin, Li -E
    Lou, Shifeng
    Song, Yanping
    Liu, Qingchi
    Zhou, Hu
    Mei, Heng
    Hu, Yu
    LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2024, 47
  • [35] A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab
    Sawas, Ahmed
    Farber, Charles M.
    Schreeder, Marshall T.
    Khalil, Mazen Y.
    Mahadevan, Daruka
    Deng, Changchun
    Amengual, Jennifer E.
    Nikolinakos, Petros G.
    Kolesar, Jill M.
    Kuhn, John G.
    Sportelli, Peter
    Miskin, Hari P.
    O'Connor, Owen A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 177 (02) : 243 - 253
  • [36] Low-Dose Humanized Anti-CD20 Monoclonal Antibody (MAb), Veltuzumab, in Adult Immune Thrombocytopenic Purpura (ITP): Initial Results of a Phase I/II Study
    Liebman, Howard A.
    Saleh, Mansoor N.
    Abassi, Rashid
    Cosgriff, Thomas M.
    Teoh, Nick
    Leoni, Matthew J.
    Wegener, William
    Goldenberg, David M.
    BLOOD, 2008, 112 (11) : 1170 - 1170
  • [37] Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis - A phase I/II randomized, blinded, placebo-controlled, dose-ranging study
    Genovese, Mark C.
    Kaine, Jeffrey L.
    Lowenstein, Mitchell B.
    Del Giudice, Jose
    Baldassare, Andrew
    Schechtman, Joy
    Fudman, Edward
    Kohen, Michael
    Gujrathi, Shelia
    Trapp, Robert G.
    Sweiss, Nadera J.
    Spaniolo, Greg
    Dummer, Wolfgang
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : 2652 - 2661
  • [38] Efficacy and Safety in Patients With Relapsing Multiple Sclerosis Who Switched to Subcutaneous Ofatumumab From Intravenous Anti-CD20 Therapies: Results From the OLIKOS Study
    Hua, Le
    Brown, Brandon
    Camacho, Elizabeth
    Greenberg, Benjamin M.
    Henry, Roland
    Houtsma, Erik
    Alvarez, Enrique
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1167 - 1168
  • [39] ITOLIZUMAB, A HUMAN ANTI-CD6 MONOCLONAL ANTIBODY, FOR TREATMENT OF RHEUMATOID ARTHRITIS: RESULTS OF A RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 STUDY
    Chopra, A.
    Srikantiah, C.
    Cg, P.
    Montero, E.
    Melarkode, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 69 - 70
  • [40] Phase I study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody MIL62 in Chinese patients with relapsed/refractory CD20-positive B-cell non-Hodgkin's lymphoma
    Shi, Y-K.
    Song, Y.
    Qin, Y.
    Zhou, K.
    Gao, Y.
    Wang, M.
    Wang, P.
    Yin, Q.
    Zhao, F.
    Ma, G.
    Li, F.
    ANNALS OF ONCOLOGY, 2020, 31 : S652 - S652
12345